CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
Blood, ISSN: 0006-4971, Vol: 121, Issue: 1, Page: 48-53
2013
- 242Citations
- 188Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations242
- Citation Indexes237
- 237
- CrossRef140
- Clinical Citations4
- PubMed Guidelines4
- Policy Citations1
- 1
- Captures188
- Readers188
- 188
Article Description
Treatment of mantle cell lymphoma (MCL) in younger patients remains a challenge. We report results of a phase 2 trial using cytarabine and rituximab as induction regimen before autologous stem cell transplantation. Patients younger than 66 years with stage 3 or 4 MCL were included. Treatment consisted of 3 courses of CHOP 21 with rituximab at the third one and 3 of R-DHAP. Responding patients were eligible for autologous stem cell transplantation with TAM6 or BEAM. Sixty patients were included. Median age was 57 years. Characteristics of patients were: BM involvement 85%, leukemic disease 48%, gastrointestinal involvement 52%, Performance Status > 16%, lactate dehydrogenase > 1N 38%, Mantle Cell Lymphoma International Prognostic Index (low 55%, intermediate 38%, high 13%). The overall response rate was 93% after (R)-CHOP and 95% after R-DHAP. Although uncommon after (R)-CHOP (12%), 57% of patients were in complete response after R-DHAP. With median follow-up of 67 months, median event-free survival is 83 months, and median overall survival is not reached. Five-year overall survival is 75%. Comparison with a previous study without rituximab shows improvement of outcome (median event-free survival, 51 vs 83 months). No toxic death or unexpected toxicities were observed. This study confirms that induction with rituximab and cytarabine-based regimens is safe and effective in MCL patients. This regimen is currently compared with R-CHOP 21 induction in a multicentric European protocol.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0006497120473239; http://dx.doi.org/10.1182/blood-2011-09-370320; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84872054301&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22718839; https://ashpublications.org/blood/article/121/1/48/31039/CHOP-and-DHAP-plus-rituximab-followed-by; https://dx.doi.org/10.1182/blood-2011-09-370320; http://europepmc.org/abstract/med/22718839; http://www.bloodjournal.org/content/121/1/48; http://www.bloodjournal.org/content/121/1/48.abstract; http://www.bloodjournal.org/content/121/1/48.full.pdf; https://f1000.com/prime/717948630#eval793455900; http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-09-370320; http://www.bloodjournal.org/content/121/1/48?sso-checked=true; http://f1000.com/717948630#eval793455900; https://ashpublications.org/blood/article-pdf/121/1/48/1363075/zh800113000048.pdf; https://signin.hematology.org/Login.aspx?vi=9&vt=9defa6a6088d2b174404aa4fe35b563f228006ecd6a40d609278f9161597931ded22a6a6c916ddd2e3692da9c32705919562d57d4a736a167148eef4da4a0ea5d9b45543dab2e725afa4641c9ef395939541b51b808b2f6acdac4e1202f1dde9253183fa3b3bd1e1b475737c47990b98&DPLF=Y; http://www.bloodjournal.org/lookup/doi/10.1182/blood-2011-09-370320?sso-checked=true; https://f1000.com/prime/717948630#eval793453739; http://www.bloodjournal.org/lookup/doi/10.1182/blood-2011-09-370320; http://f1000.com/717948630#eval793453739; http://www.bloodjournal.org/content/121/1/48.long?sso-checked=true
American Society of Hematology
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know